Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

6106 - Multi-Dimensional Immuno-Oncology Assays for Understanding the Immune System and Tumor Microenvironment

Date

20 Oct 2018

Session

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

Presenters

Fiona Hyland

Citation

Annals of Oncology (2018) 29 (suppl_8): viii14-viii57. 10.1093/annonc/mdy269

Authors

F. Hyland1, T. Looney2, R. Chaudhury1, A. Kamat1, A. Pankov1

Author affiliations

  • 1 Csd, Thermo Fisher Scientific, 94080 - South San Francisco/US
  • 2 Clinical Next-generation Sequencing Division, Thermo Fisher Scientific, 94080 - South San Francisco/US
More

Resources

Abstract 6106

Background

The promise of immuno-oncology (IO) is the potential for activating the immune system of an individual with cancer to destroy the tumor and metastases, and cause a complete and persistent response. A percentage of patients treated with checkpoint inhibitors or Car-T cell therapies exhibit complete response. However understanding all the determinants of response, and what combination of therapies can maximize efficacy and minimize adverse events, is still poorly understood. Further understanding the properties of the tumor micro-environment, the immune system, and driver mutations in the tumor provides the most comprehensive picture, enabling personalized oncology research.

Methods

We describe a suite of Oncomine assays that use a single chemistry and instrument with 20ng of input material each. The first measures patterns of gene expression of 395 genes that capture interferon and chemokine signaling, T and B cell activation, checkpoint pathway, antigen presentation, and tumor proliferation, measuring the expression of markers specific to different effector cell types. We demonstrate highly sensitive detection of low expressing genes including Interferon-Gamma. The second is the T-cell Repertoire sequencing assay. This assay uses total RNA from blood for long-amplicon TCRB chain sequencing, covering CDR1, 2 & 3. This assay provides an estimate of T cell diversity and other properties. The third is the Tumor Mutation Load assay. This 400-gene panel measures somatic mutations/Mb on FFPE samples, without requiring a matched normal. We demonstrated high reproducibility on FFPE, concordance with matched normal, correlation with exome mutation load, and accuracy on control cell lines.

Results

Together, these IO panels provide sensitive, accurate, complementary information to further elucidate biological factors underlying response, resistance, and adverse events. A single software for these diverse assays supports joint interpretation of this data.

Conclusions

These IO assays enable deep, broad, multidimensional characterization of biomarkers to explore predictors of response, optimal combination therapy, and avoidance of adverse events, accelerating research into immunotherapy for personalized oncology.

Clinical trial identification

Legal entity responsible for the study

Thermo Fisher Scientific.

Funding

Thermo Fisher Scientific.

Editorial Acknowledgement

Disclosure

F. Hyland, T. Looney, R. Chaudhury, A. Kamat, A. Pankov: Employee of Thermo Fisher Scientific.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.